

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Appointment of Zeus Capital as Joint Broker to Avacta Group plc

LONDON and PHILADELPHIA - June 30, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of Zeus Capital as a joint broker to the Company with immediate effect.

Peel Hunt and Panmure Liberum both continue in their respective roles as NOMAD and Joint Broker and Joint Broker to the Company.

Related Party Transaction

Richard Hughes, a Director of the Company, is an associate of Zeus Capital as defined under the AIM Rules. Zeus Capital is therefore a related party of the Company pursuant to the AIM Rules and the appointment of Zeus Capital including a £75,000 annual retainer due to Zeus Capital is a related party transaction. The Directors (other than Richard Hughes who is an associate of Zeus Capital) consider, having consulted with the Company's nominated adviser Peel Hunt, that the appointment of Zeus Capital including the annual retainer are fair and reasonable insofar as Shareholders are concerned.

-Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc
Michael Vinegrad, Group Communications
Director

<https://avacta.com/>

Peel Hunt (Nomad and Joint Broker)
James Steel / Chris Golden

www.peelhunt.com

Panmure Liberum (Joint Broker)
Emma Earl / Will Goode / Mark Rogers

<https://panmureliberum.com/>

Zeus (Joint Broker)
James Hornigold / George Duxberry
Dominic King

www.zeuscapital.co.uk

ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson / Stephanie
Cuthbert

avacta@icrhealthcare.com

Investor Contact
Renee Leck
THRUST Strategic Communications

renee@thrustsc.com

Media Contact
Carly Scaduto
Carly Scaduto Consulting

Carly@carlyscadutoconsulting.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEADKEDLSSEFA